Mitral valve prolapse was associated with a significantly higher risk of developing infective endocarditis compared to the general population (OR 7.83; 95% CI 5.11-12.02).
Meta-Analysis
Does mitral valve prolapse increase the risk of infective endocarditis compared to the general population?
Patients with mitral valve prolapse have an approximately 7-fold increased risk of developing infective endocarditis compared to the general population.
Effect estimate: OR 7.83 (95% CI 5.11-12.02)
AIMS: Infective endocarditis (IE) is a serious heart valvular condition. While mitral valve prolapse (MVP) has been associated with an increased risk of IE, the magnitude of this association remains poorly quantified. This systematic review aimed to better estimate the risk of developing IE among MVP patients compared with the general population. METHODS: MEDLINE, Cochrane Library (CENTRAL) and Web of Science databases were searched electronically to find all the relevant cohort and case-control studies. Pooled estimates of odds ratios (ORs) and 95 % confidence intervals (CIs) were derived by random effects meta-analysis. Heterogeneity was assessed using the I2 test. RESULTS: A total of six studies were considered eligible, and the obtained results showed that MVP patients had a higher risk of IE when compared to the general population (OR 7.83, 95 % CI 5.11, 12.02; I2 = 0 %). Posterior analysis according to the risk of bias and study design didn't show any significant variations in the direction and magnitude of the effect. CONCLUSION: The magnitude of increased risk of IE of 7-fold warrants further attention for patients with MVP. Further contemporary studies and prophylaxis studies should be considered.
Marques et al. (Fri,) conducted a meta-analysis in Mitral valve prolapse. Mitral valve prolapse vs. General population was evaluated on Infective endocarditis (OR 7.83, 95% CI 5.11-12.02). Mitral valve prolapse was associated with a significantly higher risk of developing infective endocarditis compared to the general population (OR 7.83; 95% CI 5.11-12.02).